These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

221 related articles for article (PubMed ID: 10722479)

  • 1. Horizontal transfer of parC and gyrA in fluoroquinolone-resistant clinical isolates of Streptococcus pneumoniae.
    Ferrándiz MJ; Fenoll A; Liñares J; De La Campa AG
    Antimicrob Agents Chemother; 2000 Apr; 44(4):840-7. PubMed ID: 10722479
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Contribution of mutations in gyrA and parC genes to fluoroquinolone resistance of mutants of Streptococcus pneumoniae obtained in vivo and in vitro.
    Tankovic J; Perichon B; Duval J; Courvalin P
    Antimicrob Agents Chemother; 1996 Nov; 40(11):2505-10. PubMed ID: 8913454
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Mutant prevention concentrations for single-step fluoroquinolone-resistant mutants of wild-type, efflux-positive, or ParC or GyrA mutation-containing Streptococcus pneumoniae isolates.
    Smith HJ; Walters M; Hisanaga T; Zhanel GG; Hoban DJ
    Antimicrob Agents Chemother; 2004 Oct; 48(10):3954-8. PubMed ID: 15388458
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Fluoroquinolone resistance mutations in the parC, parE, and gyrA genes of clinical isolates of viridans group streptococci.
    González I; Georgiou M; Alcaide F; Balas D; Liñares J; de la Campa AG
    Antimicrob Agents Chemother; 1998 Nov; 42(11):2792-8. PubMed ID: 9797205
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cloning and characterization of the parC and parE genes of Streptococcus pneumoniae encoding DNA topoisomerase IV: role in fluoroquinolone resistance.
    Pan XS; Fisher LM
    J Bacteriol; 1996 Jul; 178(14):4060-9. PubMed ID: 8763932
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Sparfloxacin resistance in clinical isolates of Streptococcus pneumoniae: involvement of multiple mutations in gyrA and parC genes.
    Taba H; Kusano N
    Antimicrob Agents Chemother; 1998 Sep; 42(9):2193-6. PubMed ID: 9736534
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Fluoroquinolone resistance in atypical pneumococci and oral streptococci: evidence of horizontal gene transfer of fluoroquinolone resistance determinants from Streptococcus pneumoniae.
    Ip M; Chau SS; Chi F; Tang J; Chan PK
    Antimicrob Agents Chemother; 2007 Aug; 51(8):2690-700. PubMed ID: 17548487
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Interspecies recombination contributes minimally to fluoroquinolone resistance in Streptococcus pneumoniae.
    Bast DJ; de Azavedo JC; Tam TY; Kilburn L; Duncan C; Mandell LA; Davidson RJ; Low DE
    Antimicrob Agents Chemother; 2001 Sep; 45(9):2631-4. PubMed ID: 11502541
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Primary targets of fluoroquinolones in Streptococcus pneumoniae.
    Fukuda H; Hiramatsu K
    Antimicrob Agents Chemother; 1999 Feb; 43(2):410-2. PubMed ID: 9925547
    [TBL] [Abstract][Full Text] [Related]  

  • 10. In vitro exchange of fluoroquinolone resistance determinants between Streptococcus pneumoniae and viridans streptococci and genomic organization of the parE-parC region in S. mitis.
    Janoir C; Podglajen I; Kitzis MD; Poyart C; Gutmann L
    J Infect Dis; 1999 Aug; 180(2):555-8. PubMed ID: 10395882
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Molecular evolution perspectives on intraspecific lateral DNA transfer of topoisomerase and gyrase loci in Streptococcus pneumoniae, with implications for fluoroquinolone resistance development and spread.
    Stanhope MJ; Walsh SL; Becker JA; Italia MJ; Ingraham KA; Gwynn MN; Mathie T; Poupard JA; Miller LA; Brown JR; Amrine-Madsen H
    Antimicrob Agents Chemother; 2005 Oct; 49(10):4315-26. PubMed ID: 16189113
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Relationship between mutations in parC and gyrA of clinical isolates of Streptococcus pneumoniae and resistance to ciprofloxacin and grepafloxacin.
    Stewart BA; Johnson AP; Woodford N
    J Med Microbiol; 1999 Dec; 48(12):1103-1106. PubMed ID: 10591164
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Genetic analyses of mutations contributing to fluoroquinolone resistance in clinical isolates of Streptococcus pneumoniae.
    Weigel LM; Anderson GJ; Facklam RR; Tenover FC
    Antimicrob Agents Chemother; 2001 Dec; 45(12):3517-23. PubMed ID: 11709333
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparison of gyrA and parC mutations and resistance levels among fluoroquinolone-resistant isolates and laboratory-derived mutants of oral streptococci.
    Kaneko A; Sasaki J; Shimadzu M; Kanayama A; Saika T; Kobayashi I
    J Antimicrob Chemother; 2000 Jun; 45(6):771-5. PubMed ID: 10837428
    [TBL] [Abstract][Full Text] [Related]  

  • 15. ParC subunit of DNA topoisomerase IV of Streptococcus pneumoniae is a primary target of fluoroquinolones and cooperates with DNA gyrase A subunit in forming resistance phenotype.
    Muñoz R; De La Campa AG
    Antimicrob Agents Chemother; 1996 Oct; 40(10):2252-7. PubMed ID: 8891124
    [TBL] [Abstract][Full Text] [Related]  

  • 16. ParC and GyrA may be interchangeable initial targets of some fluoroquinolones in Streptococcus pneumoniae.
    Varon E; Janoir C; Kitzis MD; Gutmann L
    Antimicrob Agents Chemother; 1999 Feb; 43(2):302-6. PubMed ID: 9925523
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Targeting of DNA gyrase in Streptococcus pneumoniae by sparfloxacin: selective targeting of gyrase or topoisomerase IV by quinolones.
    Pan XS; Fisher LM
    Antimicrob Agents Chemother; 1997 Feb; 41(2):471-4. PubMed ID: 9021211
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Viridans group streptococci are donors in horizontal transfer of topoisomerase IV genes to Streptococcus pneumoniae.
    Balsalobre L; Ferrándiz MJ; Liñares J; Tubau F; de la Campa AG
    Antimicrob Agents Chemother; 2003 Jul; 47(7):2072-81. PubMed ID: 12821449
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Activity of the new fluoroquinolone trovafloxacin (CP-99,219) against DNA gyrase and topoisomerase IV mutants of Streptococcus pneumoniae selected in vitro.
    Gootz TD; Zaniewski R; Haskell S; Schmieder B; Tankovic J; Girard D; Courvalin P; Polzer RJ
    Antimicrob Agents Chemother; 1996 Dec; 40(12):2691-7. PubMed ID: 9124824
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Contribution of topoisomerase IV and DNA gyrase mutations in Streptococcus pneumoniae to resistance to novel fluoroquinolones.
    Pestova E; Beyer R; Cianciotto NP; Noskin GA; Peterson LR
    Antimicrob Agents Chemother; 1999 Aug; 43(8):2000-4. PubMed ID: 10428926
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.